Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415690 | 0.83 | MAPT (0.61) | MAPTNPSR1HSD17B10SOS1CYP19A1 | |
| SCHEMBL7527194 | 0.83 | MAPT (0.61) | MAPTNPSR1HSD17B10SOS1CYP19A1 | |
| SCHEMBL7516374 | 0.83 | MAPT (0.61) | MAPTNPSR1HSD17B10SOS1CYP19A1 | |
| 2-Nitrobenzaldehyde SCHEMBL3323403 | 0.83 | ERN1 (0.59) | MAPTNPSR1HSD17B10XDHCA12 | |
| SCHEMBL114440 | 0.82 | MAPT (0.58) | MAPTNPSR1HSD17B10XDHCA12 | |
| SCHEMBL14935499 | 0.82 | MAPT (0.69) | MAPTNPSR1CA12SOS1CYP19A1 | |
| SCHEMBL11049170 | 0.82 | MAPT (0.69) | MAPTNPSR1CA12SOS1CYP19A1 | |
| SCHEMBL9978289 | 0.82 | MAPT (0.69) | MAPTNPSR1CA12SOS1CYP19A1 | |
| SCHEMBL27861738 | 0.82 | TDP1 (0.50) | MAPTNPSR1HSD17B10XDHCA12 | |
| SCHEMBL27722602 | 0.80 | TDP1 (0.48) | MAPTNPSR1HSD17B10XDHCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | THE UNIVERSITY OF KANSAS (US) | 2024-02-06 | — | — | US | claimed |
| CN-116179554-A | Conditional protein targeted degradation chimeric based on nucleic acid aptamer, and preparation method and application thereof | 山东师范大学 | 2023-05-30 | — | — | CN | claimed |
| CN-115720626-A | Method for locating individual molecules of a dye in a sample and method for generating a high resolution image of a structure in a sample | 阿贝锐纳仪器有限公司 | 2023-02-28 | — | — | CN | claimed |
| EP-4025711-A2 | ENHANCING SPECIFICITY OF ANALYTE BINDING | 10X Genomics, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| US-20210255074-A1 | Degradable Microsphere and Use Thereof | TSINGHUA UNIVERSITY (CN) | 2021-08-19 | — | — | US | claimed |
| CN-109589307-B | Preparation method of aptamer liposome | 华南理工大学 | 2021-05-14 | — | — | CN | claimed |
| WO-2021083459-A1 | PROCESS FOR THE SYNTHESIS OF DOPA COMPRISING A PHOTOLABILE PROTECTIVE GROUP, AND INTERMEDIATES FOR THE PREPARATION THEREOF | CHIRACON GMBH (DE) | 2021-05-06 | — | — | WO | claimed |
| EP-3808786-A1 | DEGRADABLE MICROSPHERE AND USE THEREOF | Tsinghua University (CN) | 2021-04-21 | — | — | EP | claimed |
| WO-1997005155-A1 | PHOTOLABILE 8-SUBSTITUTED CYCLIC NUCLEOTIDE ESTERS, METHODS OF PREPARING THEM AND THEIR USE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 1997-02-13 | — | — | WO | claimed |
| WO-1995029184-A1 | POLYCATIONIC NUCLEIC BASES AND OLIGONUCLEOTIDES CONTAINING SAME | UNIVERSITE LOUIS PASTEUR (FR) | 1995-11-02 | — | — | WO | claimed |
| US-5389612-A | Treating infections caused by clostridium histolyticum and pseudomonas aeruginosa; enzyme inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1995-02-14 | — | — | US | claimed |
| US-5294618-A | Psychological disorders | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-15 | — | — | US | claimed |
| EP-0410535-A2 | Octahydrobenzisoquinoline derivatives as antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-01-30 | — | — | EP | claimed |
| US-4556514-A | INTERMEDIATES FOR PRODUCTION OF CARBAPENEM OR PENEM DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-03 | — | — | US | claimed |
| US-4480096-A | COLOR FORMERS FOR PRESSURE SENSITIVE OR HEAT SENSITIVE RECORDING | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | claimed |
| EP-0106652-A1 | Beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | claimed |
| US-4435003-A | COLOR FORMERS IN PRESSURE AND/OR HEAT SENSITIVE RECORDING MATERIALS | CIBA-GEIGY CORPORATION (US) | 1984-03-06 | — | — | US | claimed |
| US-4254031-A | Synthesis for the preparation of tetracyclic compounds | AKZONA INCORPORATED (US) | 1981-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210255074-A1 | Degradable Microsphere and Use Thereof | STUB1, PSMD14, ACP1 | MAPT 1611/4885NPSR1 1980/4885HSD17B10 3836/4885 |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | EXOSC4, EXOSC5, EXOSC9 | MAPT 612/4885NPSR1 4498/4885HSD17B10 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.